Cargando…

Correction: Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy

Detalles Bibliográficos
Autores principales:	Poon, Zhiyong, Dighe, Niraja, Venkatesan, Subhashree S., Cheung, Alice M. S., Fan, Xiubo, Bari, Sudipto, Hota, Monalisa, Ghosh, Sujoy, Hwang, William Y. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756053/ https://www.ncbi.nlm.nih.gov/pubmed/30787431 http://dx.doi.org/10.1038/s41375-019-0406-z

Ejemplares similares

Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy
por: Poon, Zhiyong, et al.
Publicado: (2018)

Ex Vivo Expansion of CD34(+)CD90(+)CD49f(+) Hematopoietic Stem and Progenitor Cells from Non‐Enriched Umbilical Cord Blood with Azole Compounds
por: Bari, Sudipto, et al.
Publicado: (2018)

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs
por: Li, Hongjiao, et al.
Publicado: (2023)

Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts
por: Yahng, Seung-Ah, et al.
Publicado: (2016)

What Clonal Hematopoiesis Can Teach Us About MDS
por: Chan, Irenaeus C. C., et al.
Publicado: (2022)

Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS
por: Buck, Michèle C., et al.
Publicado: (2023)

Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis
por: Ji, Jiang, et al.
Publicado: (2020)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
por: Trowbridge, Jennifer J., et al.
Publicado: (2021)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Bone Marrow Fat and Hematopoiesis
por: Wang, Huifang, et al.
Publicado: (2018)

Traditional Chinese Medicine Containing Arsenic Treated MDS Patients Effectively through Regulating Aberrant Hypomethylation
por: Zhou, Qing-bing, et al.
Publicado: (2020)

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
por: Duchmann, M, et al.
Publicado: (2017)

Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment
por: Asada, Noboru
Publicado: (2018)

Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis
por: Wang, Xiaofang, et al.
Publicado: (2014)

Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis
por: Wang, Xiaofang, et al.
Publicado: (2021)

Interactions between MSCs and Immune Cells: Implications for Bone Healing
por: Kovach, Tracy K., et al.
Publicado: (2015)

Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow
por: Kapoor, Vaishali, et al.
Publicado: (2020)

Bone Marrow Defects and Platelet Function: A Focus on MDS and CLL
por: Luu, Sarah, et al.
Publicado: (2018)

Extramedullary Hematopoiesis in Lymphangioma - A Cytological Study
por: Kushwaha, Pritika, et al.
Publicado: (2021)

Anatomy of Hematopoiesis and Local Microenvironments in the Bone Marrow. Where to?
por: Wu, Qingqing, et al.
Publicado: (2021)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
por: Ørskov, Andreas D., et al.
Publicado: (2015)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858
por: Eksioglu, Erika A., et al.
Publicado: (2017)

The impact of chronic intermittent hypoxia on hematopoiesis and the bone marrow microenvironment
por: Alvarez-Martins, Inês, et al.
Publicado: (2016)

Myelodysplastic hematopoiesis mimicking the bone marrow in a mediastinal myelolipoma
por: Takano, Hina, et al.
Publicado: (2017)

Distinct bone marrow blood vessels differentially regulate hematopoiesis
por: Itkin, Tomer, et al.
Publicado: (2016)

Dysregulated hematopoiesis in bone marrow marks severe COVID-19
por: Wang, Xin, et al.
Publicado: (2021)

How Does Lifestyle Affect Hematopoiesis and the Bone Marrow Microenvironment?
por: Vanhie, James J., et al.
Publicado: (2022)

P706: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
por: Dimitriou, Despoina, et al.
Publicado: (2023)

Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling
por: Varney, Melinda E., et al.
Publicado: (2015)

Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment
por: Kovtonyuk, Larisa V., et al.
Publicado: (2016)

The Differentiation Balance of Bone Marrow Mesenchymal Stem Cells Is Crucial to Hematopoiesis
por: Wu, Jiang, et al.
Publicado: (2018)

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party
por: Kim, Da Jung, et al.
Publicado: (2017)

PB1989: STUDY ON THE RELATIONSHIP BETWEEN MDS AND ABNORMAL LIPID METABOLISM IN BONE MARROW MICROENVIRONMENT
por: LI, Yuchun, et al.
Publicado: (2023)

Human fetal liver MSCs are more effective than adult bone marrow MSCs for their immunosuppressive, immunomodulatory, and Foxp3(+) T reg induction capacity
por: Yu, Yi, et al.
Publicado: (2021)

Deficiency in the omega-3 lysolipid transporter Mfsd2a leads to aberrant oligodendrocyte lineage development and hypomyelination
por: Sengottuvel, Vetrivel, et al.
Publicado: (2023)

Protocol for performing consecutive bone marrow transplants in mice to study the role of marrow niche in supporting hematopoiesis
por: Gopal, Aparna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h4202olkibq30hiadcgi4d95gk